Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). [electronic resource]
Producer: 20150929Description: 2149-58 p. digitalISSN:- 1935-5548
- Aged
- Blood Glucose -- drug effects
- Diabetes Mellitus, Type 2 -- drug therapy
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Glucagon-Like Peptide 1 -- therapeutic use
- Glucagon-Like Peptides -- administration & dosage
- Glycated Hemoglobin -- analysis
- Humans
- Hypoglycemic Agents -- administration & dosage
- Immunoglobulin Fc Fragments -- administration & dosage
- Male
- Metformin -- administration & dosage
- Middle Aged
- Pyrazines -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Sitagliptin Phosphate
- Treatment Outcome
- Triazoles -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.